Old and New Drugs for Treatment of Advanced Heart Failure

Author(s): Carmelo Buttá*, Marco Roberto, Antonino Tuttolomondo, Rossella Petrantoni, Giuseppe Miceli, Luca Zappia, Antonio Pinto.

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 14 , 2020

Become EABM
Become Reviewer

Abstract:

Background: Advanced heart failure (HF) is a progressive disease with high mortality and limited medical therapeutic options. Long-term mechanical circulatory support and heart transplantation remain goldstandard treatments for these patients; however, access to these therapies is limited by the advanced age and multiple comorbidities of affected patients, as well as by the limited number of organs available.

Methods: Traditional and new drugs available for the treatment of advanced HF have been researched.

Results: To date, the cornerstone for the treatment of patients with advanced HF remains water restriction, intravenous loop diuretic therapy and inotropic support. However, many patients with advanced HF experience loop diuretics resistance and alternative therapeutic strategies to overcome this problem have been developed, including sequential nephron blockade or use of the hypertonic saline solution in combination with high-doses of furosemide. As classic inotropes augment myocardial oxygen consumption, new promising drugs have been introduced, including levosimendan, istaroxime and omecamtiv mecarbil. However, pharmacological agents still remain mainly short-term or palliative options in patients with acute decompensation or excluded from mechanical therapy.

Conclusion: Traditional drugs, especially when administered in combination, and new medicaments represent important therapeutic options in advanced HF. However, their impact on prognosis remains unclear. Large trials are necessary to clarify their therapeutic potential and prognostic role in these fragile patients.

Keywords: Dobutamine, dopamine, nitroglycerine, sodium nitroprusside, vaptans, ivabradine.

[1]
Ponikowski P, Voors AA, Anker SD, et al. ESC Scientific Document Group. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37(27): 14.
[2]
Seferović PM, Polovina M, Bauersachs J, et al. Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019; 21(5): 553-76.
[http://dx.doi.org/10.1002/ejhf.1461] [PMID: 30989768]
[3]
Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart 2007; 93(9): 1137-46.
[http://dx.doi.org/10.1136/hrt.2003.025270] [PMID: 17699180]
[4]
Seferovic PM, Ponikowski P, Anker SD, et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019; 21(10): 1169-86. Epub ahead of print
[http://dx.doi.org/10.1002/ejhf.1531] [PMID: 31129923]
[5]
Roger VL. Epidemiology of heart failure. Circ Res 2013; 113(6): 646-59.
[http://dx.doi.org/10.1161/CIRCRESAHA.113.300268] [PMID: 23989710]
[6]
Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the American college of cardiology/American heart association task force on clinical practice guidelines and the heart failure society of America. Circulation 2017; 136(6): e137-61.
[http://dx.doi.org/10.1161/CIR.0000000000000509] [PMID: 28455343]
[7]
Sharif-Barfeh Z, Beigoli S, Marouzi S, Sharifi Rad A, Asoodeh A, Chamani J. Multi-spectroscopic and HPLC studies of the interaction between estradiol and cyclophosphamide with human serum albumin: binary and ternary systems. J Solution Chem 2017; 46(2): 488-504.
[http://dx.doi.org/10.1007/s10953-017-0590-2]
[8]
Zolfagharzadeh M, Pirouzi M, Asoodeh A, Saberi MR, Chamani J. A comparison investigation of DNP-binding effects to HSA and HTF by spectroscopic and molecular modeling techniques. J Biomol Struct Dyn 2014; 32(12): 1936-52.
[http://dx.doi.org/10.1080/07391102.2013.843062] [PMID: 24125112]
[9]
Sanei H, Asoodeh A, Hamedakbari-Tusi S, Chamani J. Multi-spectroscopic investigations of aspirin and colchicine interactions with human hemoglobin: Binary and ternary systems. J Solution Chem 2011; 40(11): 1905-31.
[http://dx.doi.org/10.1007/s10953-011-9766-3]
[10]
Mokaberi P, Reyhani V, Amiri-Tehranizadeh Z, et al. New insights into the binding behavior of lomefloxacin and human hemoglobin using biophysical techniques: binary and ternary approaches. New J Chem 2019; 43(21): 8132-45.
[http://dx.doi.org/10.1039/C9NJ01048C]
[11]
Kamshad M, Jahanshah Talab M, Beigoli S, Sharifirad A, Chamani J. Use of spectroscopic and zeta potential techniques to study the interaction between lysozyme and curcumin in the presence of silver nanoparticles at different sizes. J Biomol Struct Dyn 2019; 37(8): 2030-40.
[http://dx.doi.org/10.1080/07391102.2018.1475258] [PMID: 29757090]
[12]
Crespo-Leiro MG, Metra M, Lund LH, et al. Advanced heart failure: a position statement of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2018; 20(11): 1505-35.
[http://dx.doi.org/10.1002/ejhf.1236] [PMID: 29806100]
[13]
Gheorghiade M, De Luca L, Fonarow GC, Filippatos G, Metra M, Francis GS. Pathophysiologic targets in the early phase of acute heart failure syndromes. Am J Cardiol 2005; 96(6A): 11G-7G.
[http://dx.doi.org/10.1016/j.amjcard.2005.07.016] [PMID: 16196154]
[14]
Stevenson LW, Rose EA. Left ventricular assist devices: bridges to transplantation, recovery, and destination for whom? Circulation 2003; 108(25): 3059-63.
[http://dx.doi.org/10.1161/01.CIR.0000090961.53902.99] [PMID: 14691019]
[15]
Katz JN, Waters SB, Hollis IB, Chang PP. Advanced therapies for end-stage heart failure. Curr Cardiol Rev 2015; 11(1): 63-72.
[http://dx.doi.org/10.2174/1573403X09666131117163825] [PMID: 24251460]
[16]
Sobanski PZ, Alt-Epping B, Currow DC, et al. Palliative care for people living with heart failure: European Association for Palliative Care Task Force expert position statement. Cardiovasc Res 2019; 116(1): 12-27.
[http://dx.doi.org/10.1093/cvr/cvz200] [PMID: 31386104]
[17]
Travers B, O’Loughlin C, Murphy NF, et al. Fluid restriction in the management of decompensated heart failure: no impact on time to clinical stability. J Card Fail 2007; 13(2): 128-32.
[http://dx.doi.org/10.1016/j.cardfail.2006.10.012] [PMID: 17395053]
[18]
Yancy CW, Jessup M, Bozkurt B, et al. American College of Cardiology Foundation American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62(16): e147-239.
[http://dx.doi.org/10.1016/j.jacc.2013.05.019] [PMID: 23747642]
[19]
Mullens W, Damman K, Harjola VP, et al. The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2019; 21(2): 137-55.
[http://dx.doi.org/10.1002/ejhf.1369] [PMID: 30600580]
[20]
Verbrugge FH, Grieten L, Mullens W. Management of the cardiorenal syndrome in decompensated heart failure. Cardiorenal Med 2014; 4(3-4): 176-88.
[http://dx.doi.org/10.1159/000366168] [PMID: 25737682]
[21]
Felker GM, Lee KL, Bull DA, et al. NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011; 364(9): 797-805.
[http://dx.doi.org/10.1056/NEJMoa1005419] [PMID: 21366472]
[22]
Lindenfeld J, Albert NM, Boehmer JP, et al. Heart Failure Society of America. HFSA 2010 comprehensive heart failure practice guideline. J Card Fail 2010; 16(6): e1-194.
[http://dx.doi.org/10.1016/j.cardfail.2010.04.004] [PMID: 20610207]
[23]
Lahav M, Regev A, Ra’anani P, Theodor E. Intermittent administration of furosemide vs continuous infusion preceded by a loading dose for congestive heart failure. Chest 1992; 102(3): 725-31.
[http://dx.doi.org/10.1378/chest.102.3.725] [PMID: 1516394]
[24]
Dormans TP, van Meyel JJ, Gerlag PG, Tan Y, Russel FG, Smits P. Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol 1996; 28(2): 376-82.
[http://dx.doi.org/10.1016/S0735-1097(96)00161-1] [PMID: 8800113]
[25]
Neuberg GW, Miller AB, O’Connor CM, et al. PRAISE Investigators. Prospective Randomized Amlodipine Survival Evaluation. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002; 144(1): 31-8.
[http://dx.doi.org/10.1067/mhj.2002.123144] [PMID: 12094185]
[26]
Emerman CL, DeMarco T, Costanzo MR, Peacock WF. Impact of intravenous diuretics on the outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE® Registry. J Card Fail 2004; 10: S116-7.
[http://dx.doi.org/10.1016/j.cardfail.2004.06.367]
[27]
Domanski M, Norman J, Pitt B, Haigney M, Hanlon S, Peyster E. Studies of Left Ventricular Dysfunction. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 2003; 42(4): 705-8.
[http://dx.doi.org/10.1016/S0735-1097(03)00765-4] [PMID: 12932605]
[28]
Domanski M, Tian X, Haigney M, Pitt B. Diuretic use, progressive heart failure, and death in patients in the DIG study. J Card Fail 2006; 12(5): 327-32.
[http://dx.doi.org/10.1016/j.cardfail.2006.03.006] [PMID: 16762792]
[29]
Thackray S, Easthaugh J, Freemantle N, Cleland JG. The effectiveness and relative effectiveness of intravenous inotropic drugs acting through the adrenergic pathway in patients with heart failure-a meta-regression analysis. Eur J Heart Fail 2002; 4(4): 515-29.
[http://dx.doi.org/10.1016/S1388-9842(02)00041-7] [PMID: 12167393]
[30]
Francis GS, Bartos JA, Adatya S. Inotropes. J Am Coll Cardiol 2014; 63(20): 2069-78.
[http://dx.doi.org/10.1016/j.jacc.2014.01.016] [PMID: 24530672]
[31]
Goldberg LI. Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol Rev 1972; 24(1): 1-29.
[PMID: 4554480]
[32]
Trinh J, Palmer K. Inotropes. Anaesth Intensive Care 2012; 13: 492-8.
[http://dx.doi.org/10.1016/j.mpaic.2012.08.012]
[33]
Guglin M, Kaufman M. Inotropes do not increase mortality in advanced heart failure. Int J Gen Med 2014; 7: 237-51.
[http://dx.doi.org/10.2147/IJGM.S62549] [PMID: 24899821]
[34]
O’Connor CM, Gattis WA, Uretsky BF, et al. Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 1999; 138(1 Pt 1): 78-86.
[http://dx.doi.org/10.1016/S0002-8703(99)70250-4] [PMID: 10385768]
[35]
Packer M, Carver JR, Rodeheffer RJ, et al. The PROMISE Study Research Group. Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 1991; 325(21): 1468-75.
[http://dx.doi.org/10.1056/NEJM199111213252103] [PMID: 1944425]
[36]
Amsallem E, Kasparian C, Haddour G, Boissel JP, Nony P. Phosphodiesterase III inhibitors for heart failure. Cochrane Database Syst Rev 2005; (1): CD002230
[PMID: 15674893]
[37]
Nanas JN, Kontoyannis DA, Alexopoulos GP, et al. Long-term intermittent dobutamine infusion combined with oral amiodarone improves the survival of patients with severe congestive heart failure. Chest 2001; 119(4): 1173-8.
[http://dx.doi.org/10.1378/chest.119.4.1173] [PMID: 11296186]
[38]
Nanas JN, Tsagalou EP, Kanakakis J, et al. Long-term intermittent dobutamine infusion, combined with oral amiodarone for end-stage heart failure: a randomized double-blind study. Chest 2004; 125(4): 1198-204.
[http://dx.doi.org/10.1378/chest.125.4.1198] [PMID: 15078725]
[39]
Drakos SG, Kanakakis JV, Nanas S, et al. Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure. J Cardiovasc Pharmacol 2009; 53(2): 157-61.
[http://dx.doi.org/10.1097/FJC.0b013e31819846cd] [PMID: 19188832]
[40]
Gandhi S, Mosleh W, Myers RB. Hypertonic saline with furosemide for the treatment of acute congestive heart failure: a systematic review and meta-analysis. Int J Cardiol 2014; 173(2): 139-45.
[http://dx.doi.org/10.1016/j.ijcard.2014.03.020] [PMID: 24679680]
[41]
Jardim SI, Ramos Dos Santos L, Araújo I, et al. A 2018 overview of diuretic resistance in heart failure. Rev Port Cardiol 2018; 37(11): 935-45.
[http://dx.doi.org/10.1016/j.repc.2018.03.014] [PMID: 30470451]
[42]
Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 2010; 56(19): 1527-34.
[http://dx.doi.org/10.1016/j.jacc.2010.06.034] [PMID: 21029871]
[43]
Bart BA, Goldsmith SR, Lee KL, et al. Heart Failure Clinical Research Network. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012; 367(24): 2296-304.
[http://dx.doi.org/10.1056/NEJMoa1210357] [PMID: 23131078]
[44]
Butler J, Anstrom KJ, Felker GM, et al. National heart lung and blood institute heart failure clinical research network. Efficacy and safety of spironolactone in acute heart failure: The ATHENA-HF randomized clinical trial. JAMA Cardiol 2017; 2(9): 950-8.
[http://dx.doi.org/10.1001/jamacardio.2017.2198] [PMID: 28700781]
[45]
Shchekochikhin D, Al Ammary F, Lindenfeld JA, Schrier R. Role of diuretics and ultrafiltration in congestive heart failure. Pharmaceuticals (Basel) 2013; 6(7): 851-66.
[http://dx.doi.org/10.3390/ph6070851] [PMID: 24276318]
[46]
Knauf H, Mutschler E. Sequential nephron blockade breaks resistance to diuretics in edematous states. J Cardiovasc Pharmacol 1997; 29(3): 367-72.
[http://dx.doi.org/10.1097/00005344-199703000-00010] [PMID: 9125675]
[47]
Mullens W, Verbrugge FH, Nijst P, et al. Rationale and design of the ADVOR (Acetazolamide in Decompensated Heart Failure with Volume Overload) trial. Eur J Heart Fail 2018; 20(11): 1591-600.
[http://dx.doi.org/10.1002/ejhf.1307] [PMID: 30238574]
[48]
McMurray JJV, Solomon SD, Inzucchi SE, et al. DAPA-HF trial committees and investigators. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 2019; 381(21): 1995-2008. Epub ahead of print
[http://dx.doi.org/10.1056/NEJMoa1911303] [PMID: 31535829]
[49]
Paterna S, Di Pasquale P, Parrinello G, et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure. Eur J Heart Fail 2000; 2(3): 305-13.
[http://dx.doi.org/10.1016/S1388-9842(00)00094-5] [PMID: 10938493]
[50]
Licata G, Di Pasquale P, Parrinello G, et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects. Am Heart J 2003; 145(3): 459-66.
[http://dx.doi.org/10.1067/mhj.2003.166] [PMID: 12660669]
[51]
Liszkowski M, Nohria A. Rubbing salt into wounds: hypertonic saline to assist with volume removal in heart failure. Curr Heart Fail Rep 2010; 7(3): 134-9.
[http://dx.doi.org/10.1007/s11897-010-0018-4] [PMID: 20607462]
[52]
Paterna S, Parrinello G, Cannizzaro S, et al. Medium term effects of different dosage of diuretic, sodium, and fluid administration on neurohormonal and clinical outcome in patients with recently compensated heart failure. Am J Cardiol 2009; 103(1): 93-102.
[http://dx.doi.org/10.1016/j.amjcard.2008.08.043] [PMID: 19101237]
[53]
Parrinello G, Di Pasquale P, Licata G, et al. Long-term effects of dietary sodium intake on cytokines and neurohormonal activation in patients with recently compensated congestive heart failure. J Card Fail 2009; 15(10): 864-73.
[http://dx.doi.org/10.1016/j.cardfail.2009.06.002] [PMID: 19944363]
[54]
Paterna S, Di Pasquale P, Parrinello G, et al. Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study. J Am Coll Cardiol 2005; 45(12): 1997-2003.
[http://dx.doi.org/10.1016/j.jacc.2005.01.059] [PMID: 15963399]
[55]
Tuttolomondo A, Pinto A, Di Raimondo D, et al. Changes in natriuretic peptide and cytokine plasma levels in patients with heart failure, after treatment with high dose of furosemide plus hypertonic saline solution (HSS) and after a saline loading. Nutr Metab Cardiovasc Dis 2011; 21(5): 372-9.
[http://dx.doi.org/10.1016/j.numecd.2009.10.014] [PMID: 20346637]
[56]
ter Maaten JM, Dunning AM, Valente MA, et al. Diuretic response in acute heart failure-an analysis from ASCEND-HF. Am Heart J 2015; 170(2): 313-21.
[http://dx.doi.org/10.1016/j.ahj.2015.05.003] [PMID: 26299229]
[57]
Vazir A, Cowie MR. Decongestion: Diuretics and other therapies for hospitalized heart failure. Indian Heart J 2016; 68(Suppl. 1): S61-8.
[http://dx.doi.org/10.1016/j.ihj.2015.10.386] [PMID: 27056656]
[58]
Bowman BN, Nawarskas JJ, Anderson JR. Treating diuretic resistance: an overview. Cardiol Rev 2016; 24(5): 256-60.
[http://dx.doi.org/10.1097/CRD.0000000000000116] [PMID: 27465540]
[59]
Wan SH, Stevens SR, Borlaug BA, et al. Differential response to low-dose dopamine or low-dose nesiritide in acute heart failure with reduced or preserved ejection fraction: results from the ROSE AHF Trial (Renal Optimization Strategies Evaluation in Acute Heart Failure). Circ Heart Fail 2016; 9(8) e002593
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.115.002593] [PMID: 27512103]
[60]
Triposkiadis FK, Butler J, Karayannis G, et al. Efficacy and safety of high dose versus low dose furosemide with or without dopamine infusion: the Dopamine in Acute Decompensated Heart Failure II (DAD-HF II) trial. Int J Cardiol 2014; 172(1): 115-21.
[http://dx.doi.org/10.1016/j.ijcard.2013.12.276] [PMID: 24485633]
[61]
Parle NM, Thomas MD, Dembo L, Best M, Driscoll GO. Repeated infusions of levosimendan: well tolerated and improves functional capacity in decompensated heart failure - a single-centre experience. Heart Lung Circ 2008; 17(3): 206-10.
[http://dx.doi.org/10.1016/j.hlc.2007.10.014] [PMID: 18242130]
[62]
Nieminen MS, Altenberger J, Ben-Gal T, et al. Repetitive use of levosimendan for treatment of chronic advanced heart failure: clinical evidence, practical considerations, and perspectives: an expert panel consensus. Int J Cardiol 2014; 174(2): 360-7.
[http://dx.doi.org/10.1016/j.ijcard.2014.04.111] [PMID: 24780540]
[63]
Papp Z, Csapó K, Pollesello P, Haikala H, Edes I. Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. Cardiovasc Drug Rev 2005; 23(1): 71-98.
[http://dx.doi.org/10.1111/j.1527-3466.2005.tb00158.x] [PMID: 15867949]
[64]
Ahmad T, Miller PE, McCullough M, et al. Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials. Eur J Heart Fail 2019; 21(9): 1064-78.
[http://dx.doi.org/10.1002/ejhf.1557] [PMID: 31407860]
[65]
Antila S, Sundberg S, Lehtonen LA. Clinical pharmacology of levosimendan. Clin Pharmacokinet 2007; 46(7): 535-52.
[http://dx.doi.org/10.2165/00003088-200746070-00001] [PMID: 17596101]
[66]
Lilleberg J, Laine M, Palkama T, Kivikko M, Pohjanjousi P, Kupari M. Duration of the haemodynamic action of a 24-h infusion of levosimendan in patients with congestive heart failure. Eur J Heart Fail 2007; 9(1): 75-82.
[http://dx.doi.org/10.1016/j.ejheart.2006.04.012] [PMID: 16829185]
[67]
Nieminen MS, Fruhwald S, Heunks LM, et al. Levosimendan: current data, clinical use and future development. Heart Lung Vessel 2013; 5(4): 227-45.
[PMID: 24364017]
[68]
Pierrakos C, Velissaris D, Franchi F, Muzzi L, Karanikolas M, Scolletta S. Levosimendan in critical illness: a literature review. J Clin Med Res 2014; 6(2): 75-85.
[http://dx.doi.org/10.14740/jocmr1702w] [PMID: 24578748]
[69]
Lunghetti S, Palmerini E, Urselli R, et al. Effects of levosimendan without loading dose on systolic and diastolic function in patients with end-stage heart failure. Cardiol J 2011; 18(5): 532-7.
[http://dx.doi.org/10.5603/CJ.2011.0009] [PMID: 21947989]
[70]
Packer M, Colucci W, Fisher L, et al. REVIVE Heart Failure Study Group. Effect of levosimendan on the short-term clinical course of patients with acutely decompensated heart failure. JACC Heart Fail 2013; 1(2): 103-11.
[http://dx.doi.org/10.1016/j.jchf.2012.12.004] [PMID: 24621834]
[71]
Mebazaa A, Nieminen MS, Packer M, et al. SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007; 297(17): 1883-91.
[http://dx.doi.org/10.1001/jama.297.17.1883] [PMID: 17473298]
[72]
Nieminen MS, Cleland JG, Eha J, et al. Oral levosimendan in patients with severe chronic heart failure --the PERSIST study. Eur J Heart Fail 2008; 10(12): 1246-54.
[http://dx.doi.org/10.1016/j.ejheart.2008.09.006] [PMID: 18945637]
[73]
Bonios MJ, Terrovitis JV, Drakos SG, et al. Comparison of three different regimens of intermittent inotrope infusions for end stage heart failure. Int J Cardiol 2012; 159(3): 225-9.
[http://dx.doi.org/10.1016/j.ijcard.2011.03.013] [PMID: 21481958]
[74]
Nanas JN, Papazoglou P, Tsagalou EP, et al. Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine alone. Am J Cardiol 2005; 95(6): 768-71.
[http://dx.doi.org/10.1016/j.amjcard.2004.11.033] [PMID: 15757608]
[75]
Silvetti S, Greco T, Di Prima AL, et al. Intermittent levosimendan improves mid-term survival in chronic heart failure patients: meta-analysis of randomised trials. Clin Res Cardiol 2014; 103(7): 505-13.
[http://dx.doi.org/10.1007/s00392-013-0649-z] [PMID: 24368740]
[76]
Oliva F, Perna E, Marini M, et al. RELEVANT-HF study group. Scheduled intermittent inotropes for Ambulatory Advanced Heart Failure. The RELEVANT-HF multicentre collaboration. Int J Cardiol 2018; 272: 255-9.
[http://dx.doi.org/10.1016/j.ijcard.2018.08.048] [PMID: 30131229]
[77]
Altenberger J, Parissis JT, Costard-Jaeckle A, et al. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial. Eur J Heart Fail 2014; 16(8): 898-906.
[http://dx.doi.org/10.1002/ejhf.118] [PMID: 24920349]
[78]
Comín-Colet J, Manito N, Segovia-Cubero J, et al. LION-HEART Study Investigators. Efficacy and safety of intermittent intravenous outpatient administration of levosimendan in patients with advanced heart failure: the LION-HEART multicentre randomised trial. Eur J Heart Fail 2018; 20(7): 1128-36.
[http://dx.doi.org/10.1002/ejhf.1145] [PMID: 29405611]
[79]
Oliva F, Comin-Colet J, Fedele F, et al. Repetitive levosimendan treatment in the management of advanced heart failure. Eur Heart J Suppl 2018; 20(Suppl. I): I11-20.
[http://dx.doi.org/10.1093/eurheartj/suy040] [PMID: 30555280]
[80]
Stevenson LW, Pagani FD, Young JB, et al. INTERMACS profiles of advanced heart failure: the current picture. J Heart Lung Transplant 2009; 28(6): 535-41.
[http://dx.doi.org/10.1016/j.healun.2009.02.015] [PMID: 19481012]
[81]
Hasenfuss G, Teerlink JR. Cardiac inotropes: current agents and future directions. Eur Heart J 2011; 32(15): 1838-45.
[http://dx.doi.org/10.1093/eurheartj/ehr026] [PMID: 21388993]
[82]
Gheorghiade M, Blair JE, Filippatos GS, et al. HORIZON-HF Investigators. Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. J Am Coll Cardiol 2008; 51(23): 2276-85.
[http://dx.doi.org/10.1016/j.jacc.2008.03.015] [PMID: 18534276]
[83]
Greenberg B, Butler J, Felker GM, et al. Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet 2016; 387(10024): 1178-86.
[http://dx.doi.org/10.1016/S0140-6736(16)00082-9] [PMID: 26803443]
[84]
Cleland JG, Teerlink JR, Senior R, et al. The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial. Lancet 2011; 378(9792): 676-83.
[http://dx.doi.org/10.1016/S0140-6736(11)61126-4] [PMID: 21856481]
[85]
Teerlink JR, Felker GM, McMurray JJV, et al. ATOMIC-AHF Investigators. Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: The ATOMIC-AHF study. J Am Coll Cardiol 2016; 67(12): 1444-55.
[http://dx.doi.org/10.1016/j.jacc.2016.01.031] [PMID: 27012405]
[86]
Sabbah HN, Tocchetti CG, Wang M, et al. Nitroxyl (HNO): A novel approach for the acute treatment of heart failure. Circ Heart Fail 2013; 6(6): 1250-8.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.113.000632] [PMID: 24107588]
[87]
den Uil CA, Caliskan K, Lagrand WK, et al. Dose-dependent benefit of nitroglycerin on microcirculation of patients with severe heart failure. Intensive Care Med 2009; 35(11): 1893-9.
[http://dx.doi.org/10.1007/s00134-009-1591-4] [PMID: 19639300]
[88]
Loh E, Elkayam U, Cody R, Bristow M, Jaski B, Colucci WS. A randomized multicenter study comparing the efficacy and safety of intravenous milrinone and intravenous nitroglycerin in patients with advanced heart failure. J Card Fail 2001; 7(2): 114-21.
[http://dx.doi.org/10.1054/jcaf.2001.24136] [PMID: 11420762]
[89]
Mullens W, Abrahams Z, Francis GS, et al. Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol 2008; 52(3): 200-7.
[http://dx.doi.org/10.1016/j.jacc.2008.02.083] [PMID: 18617068]
[90]
Capomolla S, Febo O, Opasich C, et al. Chronic infusion of dobutamine and nitroprusside in patients with end-stage heart failure awaiting heart transplantation: safety and clinical outcome. Eur J Heart Fail 2001; 3(5): 601-10.
[http://dx.doi.org/10.1016/S1388-9842(01)00165-9] [PMID: 11595609]
[91]
McMurray JJ, Adamopoulos S, Anker SD, et al. Task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of Cardiology; ESC Committee for Practice Guidelines. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012; 14(8): 803-69.
[http://dx.doi.org/10.1093/eurjhf/hfs105] [PMID: 22828712]
[92]
Mills RM, Hobbs RE, Young JB. “BNP” for heart failure: role of nesiritide in cardiovascular therapeutics. Congest Heart Fail 2002; 8(5): 270-3.
[http://dx.doi.org/10.1111/j.1527-5299.2002.01154.x] [PMID: 12368590]
[93]
Feldman D, Menachemi DM, Abraham WT, Wexler RK. Management strategies for stage-D patients with acute heart failure. Clin Cardiol 2008; 31(7): 297-301.
[http://dx.doi.org/10.1002/clc.20251] [PMID: 17957741]
[94]
Chung ES, Menon SG, Daly KA, et al. Safety and tolerability of serial home infusions of nesiritide for advanced heart failure. Am J Cardiol 2006; 97(9): 1370-3.
[http://dx.doi.org/10.1016/j.amjcard.2005.11.066] [PMID: 16635613]
[95]
Yancy CW, Singh A. Potential applications of outpatient nesiritide infusions in patients with advanced heart failure and concomitant renal insufficiency (from the Follow-Up Serial Infusions of Nesiritide [FUSION I] trial). Am J Cardiol 2006; 98(2): 226-9.
[http://dx.doi.org/10.1016/j.amjcard.2006.01.081] [PMID: 16828598]
[96]
Schwarz ER, Najam S, Akel R, Sulimanjee N, Bionat S, Rosanio S. Intermittent outpatient nesiritide infusion reduces hospital admissions in patients with advanced heart failure. J Cardiovasc Pharmacol Ther 2007; 12(3): 232-6.
[http://dx.doi.org/10.1177/1074248407303657] [PMID: 17875951]
[97]
O’Dell KM, Kalus JS, Kucukarslan S, Czerska B. Nesiritide for secondary pulmonary hypertension in patients with end-stage heart failure. Am J Health Syst Pharm 2005; 62(6): 606-9.
[http://dx.doi.org/10.1093/ajhp/62.6.606] [PMID: 15757881]
[98]
Yancy CW, Krum H, Massie BM, et al. FUSION II Investigators. Safety and efficacy of outpatient nesiritide in patients with advanced heart failure: results of the Second Follow-Up Serial Infusions of Nesiritide (FUSION II) trial. Circ Heart Fail 2008; 1(1): 9-16.
[http://dx.doi.org/10.1161/CIRCHEARTFAILURE.108.767483] [PMID: 19808265]
[99]
Elkayam U, Bitar F. Effects of nitrates and hydralazine in heart failure: clinical evidence before the african american heart failure trial. Am J Cardiol 2005; 96(7B): 37i-43i.
[http://dx.doi.org/10.1016/j.amjcard.2005.07.031] [PMID: 16226934]
[100]
Carson P, Ziesche S, Johnson G, Cohn JN. Vasodilator-Heart Failure Trial Study Group. Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. J Card Fail 1999; 5(3): 178-87.
[http://dx.doi.org/10.1016/S1071-9164(99)90001-5] [PMID: 10496190]
[101]
Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N Engl J Med 1986; 314(24): 1547-52.
[http://dx.doi.org/10.1056/NEJM198606123142404] [PMID: 3520315]
[102]
Taylor AL, Ziesche S, Yancy C, et al. African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med 2004; 351(20): 2049-57.
[http://dx.doi.org/10.1056/NEJMoa042934] [PMID: 15533851]
[103]
Mullens W, Abrahams Z, Francis GS, et al. Usefulness of Isosorbide Dinitrate and Hydralazine as add-on therapy in patients discharged for advanced decompensated heart failure. Am J Cardiol 2009; 103(8): 1113-9.
[http://dx.doi.org/10.1016/j.amjcard.2008.12.028] [PMID: 19361599]
[104]
Taylor AL, Sabolinski ML, Tam SW, et al. A-HeFT Investigators. Effect of fixed-dose combined isosorbide dinitrate/hydralazine in elderly patients in the African-American heart failure trial. J Card Fail 2012; 18(8): 600-6.
[http://dx.doi.org/10.1016/j.cardfail.2012.06.526] [PMID: 22858074]
[105]
Böhm M, Swedberg K, Komajda M, et al. SHIFT Investigators. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010; 376(9744): 886-94.
[http://dx.doi.org/10.1016/S0140-6736(10)61259-7] [PMID: 20801495]
[106]
Bui AL, Grau-Sepulveda MV, Hernandez AF, et al. Admission heart rate and in-hospital outcomes in patients hospitalized for heart failure in sinus rhythm and in atrial fibrillation. Am Heart J 2013; 165(4): 567-74.e6.
[http://dx.doi.org/10.1016/j.ahj.2013.01.007] [PMID: 23537974]
[107]
Rushworth GF, Lambrakis P, Leslie SJ. Ivabradine: a new rate-limiting therapy for coronary artery disease and heart failure. Ther Adv Drug Saf 2011; 2(1): 19-28.
[http://dx.doi.org/10.1177/2042098610393209] [PMID: 25083199]
[108]
De Ferrari GM, Mazzuero A, Agnesina L, et al. Favourable effects of heart rate reduction with intravenous administration of ivabradine in patients with advanced heart failure. Eur J Heart Fail 2008; 10(6): 550-5.
[http://dx.doi.org/10.1016/j.ejheart.2008.04.005] [PMID: 18486549]
[109]
Haechl N, Ebner J, Hilber K, Todt H, Koenig X. Pharmacological profile of the bradycardic agent ivabradine on human cardiac ion channels. Cell Physiol Biochem 2019; 53(1): 36-48.
[http://dx.doi.org/10.33594/000000119] [PMID: 31169990]
[110]
Bocchi EA, Salemi VMC. Ivabradine for treatment of heart failure. Expert Opin Drug Saf 2019; 18(5): 393-402.
[http://dx.doi.org/10.1080/14740338.2019.1612873] [PMID: 31074301]
[111]
Böhm M, Borer J, Ford I, et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013; 102(1): 11-22.
[http://dx.doi.org/10.1007/s00392-012-0467-8] [PMID: 22575988]
[112]
Borer JS, Böhm M, Ford I, et al. SHIFT Investigators. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). Am J Cardiol 2014; 113(3): 497-503.
[http://dx.doi.org/10.1016/j.amjcard.2013.10.033] [PMID: 24332674]
[113]
Lofrano-Alves MS, Issa VS, Biselli B, Chizzola P, Ayub-Ferreira SM, Bocchi EA. Control of sinus tachycardia as an additional therapy in patients with decompensated heart failure (CONSTATHE-DHF): A randomized, double-blind, placebo-controlled trial. J Heart Lung Transplant 2016; 35(10): 1260-4.
[http://dx.doi.org/10.1016/j.healun.2016.06.005] [PMID: 27469019]
[114]
Heusch G. Heart rate and heart failure. Not a simple relationship. Circ J 2011; 75(2): 229-36.
[http://dx.doi.org/10.1253/circj.CJ-10-0925] [PMID: 21041970]
[115]
Gallet R, Ternacle J, Damy T, et al. Hemodynamic effects of Ivabradine in addition to dobutamine in patients with severe systolic dysfunction. Int J Cardiol 2014; 176(2): 450-5.
[http://dx.doi.org/10.1016/j.ijcard.2014.07.093] [PMID: 25129291]
[116]
Goldsmith SR. Baroreflex control of vasopressin secretion in normal humans Vasopressin: cellular and integrative functions. New York: Raven Press 1988; pp. 389-97.
[117]
Udelson JE, Orlandi C, Ouyang J, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 2008; 52(19): 1540-5.
[http://dx.doi.org/10.1016/j.jacc.2008.08.013] [PMID: 19007589]
[118]
Izumi Y, Miura K, Iwao H. Therapeutic potential of vasopressin-receptor antagonists in heart failure. J Pharmacol Sci 2014; 124(1): 1-6.
[http://dx.doi.org/10.1254/jphs.13R13CP] [PMID: 24401675]
[119]
Atsumi W, Tani S, Tachibana E, Hirayama A. Combined evaluation of the plasma arginine vasopressin and noradrenaline levels may be a useful predictor of the prognosis of patients with acute decompensated heart failure. Int Heart J 2018; 59(4): 791-801.
[http://dx.doi.org/10.1536/ihj.17-244] [PMID: 29794379]
[120]
Kiuchi S, Ikeda T. Hemodynamic and hormonal effects of tolvaptan for heart failure. Intern Med 2019; 58(4): 471-5.
[http://dx.doi.org/10.2169/internalmedicine.1697-18] [PMID: 30210135]
[121]
Holmes CL, Landry DW, Granton JT. Science review: Vasopressin and the cardiovascular system part 1--receptor physiology. Crit Care 2003; 7(6): 427-34.
[http://dx.doi.org/10.1186/cc2337] [PMID: 14624682]
[122]
Balling L, Gustafsson F. Copeptin in heart failure. Adv Clin Chem 2016; 73: 29-64.
[http://dx.doi.org/10.1016/bs.acc.2015.10.006] [PMID: 26975969]
[123]
Imamura T, Kinugawa K, Fujino T, et al. Increased urine aquaporin-2 relative to plasma arginine vasopressin is a novel marker of response to tolvaptan in patients with decompensated heart failure. Circ J 2014; 78(9): 2240-9.
[http://dx.doi.org/10.1253/circj.CJ-14-0244] [PMID: 24954239]
[124]
Imamura T, Kinugawa K, Shiga T, et al. Novel criteria of urine osmolality effectively predict response to tolvaptan in decompensated heart failure patients--association between non-responders and chronic kidney disease. Circ J 2013; 77(2): 397-404.
[http://dx.doi.org/10.1253/circj.CJ-12-0971] [PMID: 23131721]
[125]
Imamura T, Kinugawa K, Minatsuki S, et al. Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients. Circ J 2013; 77(5): 1208-13.
[http://dx.doi.org/10.1253/circj.CJ-12-1328] [PMID: 23318562]
[126]
Kadota M, Ise T, Yagi S, et al. Response prediction and influence of tolvaptan in chronic heart failure patients considering the interaction of the renin angiotensin aldosterone system and arginine vasopressin. Int Heart J 2016; 57(4): 461-5.
[http://dx.doi.org/10.1536/ihj.15-491] [PMID: 27357439]
[127]
Matsuzaki M, Hori M, Izumi T, Fukunami M. Tolvaptan Investigators. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther 2011; 25(Suppl. 1): S33-45.
[http://dx.doi.org/10.1007/s10557-011-6304-x] [PMID: 22120092]
[128]
Wang C, Xiong B, Cai L. Effects of Tolvaptan in patients with acute heart failure: a systematic review and meta-analysis. BMC Cardiovasc Disord 2017; 17(1): 164.
[http://dx.doi.org/10.1186/s12872-017-0598-y] [PMID: 28633650]
[129]
Xiong B, Huang Y, Tan J, et al. The short-term and long-term effects of tolvaptan in patients with heart failure: a meta-analysis of randomized controlled trials. Heart Fail Rev 2015; 20(6): 633-42.
[http://dx.doi.org/10.1007/s10741-015-9503-x] [PMID: 26334632]
[130]
Yang CJ, Yang J, Yang J, Fan ZX. Arginine vasopressin antagonist tolvaptan in the treatment of heart failure: a meta-analysis of randomized controlled trials. Int J Clin Exp Med 2015; 8(12): 22117-28.
[PMID: 26885186]
[131]
Alskaf E, Tridente A, Al-Mohammad A. Tolvaptan for heart failure, systematic review and meta-analysis of trials. J Cardiovasc Pharmacol 2016; 68(3): 196-203.
[http://dx.doi.org/10.1097/FJC.0000000000000405] [PMID: 27159621]
[132]
Kiuchi S, Hisatake S, Kabuki T, et al. Comparable effect of tolvaptan in heart failure patients with preserved or reduced ejection fraction. Clin Exp Hypertens 2019; 22: 1-8.
[http://dx.doi.org/10.1080/10641963.2019.1583244] [PMID: 30793983]
[133]
Hauptman PJ, Burnett J, Gheorghiade M, et al. Everest Investigators. Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. J Card Fail 2013; 19(6): 390-7.
[http://dx.doi.org/10.1016/j.cardfail.2013.04.001] [PMID: 23743487]
[134]
Shirakabe A, Hata N, Yamamoto M, et al. Immediate administration of tolvaptan prevents the exacerbation of acute kidney injury and improves the mid-term prognosis of patients with severely decompensated acute heart failure. Circ J 2014; 78(4): 911-21.
[http://dx.doi.org/10.1253/circj.CJ-13-1255] [PMID: 24553192]
[135]
Matsukawa R, Kubota T, Okabe M, Yamamoto Y. Early use of V2 receptor antagonists is associated with a shorter hospital stay and reduction in in-hospital death in patients with decompensated heart failure. Heart Vessels 2016; 31(10): 1650-8.
[http://dx.doi.org/10.1007/s00380-015-0780-z] [PMID: 26676672]
[136]
Konstam MA, Kiernan M, Chandler A, et al. SECRET of CHF Investigators, Coordinators, and Committee Members. Short-term effects of tolvaptan in patients with acute heart failure and volume overload. J Am Coll Cardiol 2017; 69(11): 1409-19.
[http://dx.doi.org/10.1016/j.jacc.2016.12.035] [PMID: 28302292]
[137]
Oxberry SG, Torgerson DJ, Bland JM, Clark AL, Cleland JG, Johnson MJ. Short-term opioids for breathlessness in stable chronic heart failure: a randomized controlled trial. Eur J Heart Fail 2011; 13(9): 1006-12.
[http://dx.doi.org/10.1093/eurjhf/hfr068] [PMID: 21712288]
[138]
Oxberry SG, Bland JM, Clark AL, Cleland JG, Johnson MJ. Repeat dose opioids may be effective for breathlessness in chronic heart failure if given for long enough. J Palliat Med 2013; 16(3): 250-5.
[http://dx.doi.org/10.1089/jpm.2012.0270] [PMID: 23368980]
[139]
Johnson MJ, McDonagh TA, Harkness A, McKay SE, Dargie HJ. Morphine for the relief of breathlessness in patients with chronic heart failure--a pilot study. Eur J Heart Fail 2002; 4(6): 753-6.
[http://dx.doi.org/10.1016/S1388-9842(02)00158-7] [PMID: 12453546]
[140]
Godfrey C, Harrison MB, Medves J, Tranmer JE. The symptom of pain with heart failure: a systematic review. J Card Fail 2006; 12(4): 307-13.
[http://dx.doi.org/10.1016/j.cardfail.2006.01.006] [PMID: 16679265]
[141]
Sudano I, Flammer AJ, Périat D, et al. Acetaminophen increases blood in patients with coronary artery disease. Circulation 2010; 122: 1789-96.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.110.956490] [PMID: 20956208]
[142]
Ghosh RK, Ball S, Prasad V, Gupta A. Depression in heart failure: Intricate relationship, pathophysiology and most updated evidence of interventions from recent clinical studies. Int J Cardiol 2016; 224: 170-7.
[http://dx.doi.org/10.1016/j.ijcard.2016.09.063] [PMID: 27657469]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 14
Year: 2020
Page: [1571 - 1583]
Pages: 13
DOI: 10.2174/1381612826666191226165402
Price: $65

Article Metrics

PDF: 29
HTML: 1